Monitor outcomes to ensure long-term PRRS control success. Track diagnostic results and pig performance data across sow, grow-finish, and whole production systems to detect low-level virus circulation, guide decisions, and move herds toward stable or negative status.
The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.
The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.
The objective of this report was to summarize experimental data on PRRSV MLV efficacy following challenge with genetically diverse PRRSV field isolates.
Use of a modified-live PRRSV vaccine significantly reduced lung lesions in multiple challenge models.
The objective of this study was to evaluate several adjuvants and/or immunomodulators in combination with Ingelvac PRRS MLV and investigate potential clinical or immunological improvements in vivo.
The results of this study confirmed that in a severe heterologous virulent challenge respiratory model, Ingelvac PRRS MLV provided significant levels of protection.
The objective of this report was to summarize the data from 16 independent laboratory trials, which evaluated Ingelvac PRRS and Ingelvac ATP vaccine efficacy in the respiratory model.
Vaccination was efficacious against a wide variety of heterologous challenge strains with varied isolation times, genetic sequences, and relative virulence.
The objective of this study was to evaluate the efficacy of Ingelvac PRRS MLV, Prevacent PRRS and a novel experimental PRRSV MLV vaccine in a pig respiratory challenge model.
Ingelvac PRRS MLV group demonstrated a significant improvement in ADWG and reduction in the level of viremia compared to both the Prevacent PRRS and non-vaccinated control groups during the post-challenge period.